Department of General Surgery, Affiliated Hospital of Jiangnan University, Wuxi, China; Laboratory of Genomic and Precision Medicine, Wuxi School of Medicine, Jiangnan University, 1800 Lihu Avenue, Wuxi, China.
Department of General Surgery, Affiliated Hospital of Jiangnan University, Wuxi, China; Laboratory of Genomic and Precision Medicine, Wuxi School of Medicine, Jiangnan University, 1800 Lihu Avenue, Wuxi, China; Joint Primate Research Center for Chronic Diseases, Jiangnan University and Institute of Zoology, Guangdong Academy of Science, Guangzhou, China; Guangdong Key Laboratory of Animal Conservation and Resource Utilization, Guangdong Public Laboratory of Wild Animal Conservation and Utilization, Institute of Zoology, Guangdong Academy of Sciences, Guangzhou, China.
Biochem Biophys Res Commun. 2024 Feb 5;695:149373. doi: 10.1016/j.bbrc.2023.149373. Epub 2023 Dec 14.
Recent studies have revealed that tumor immunotherapy resistance is influenced by ADAR-mediated RNA editing, but its targets remain unelucidated. Our current study identified the poliovirus receptor (PVR) oncogene, which encodes an immune checkpoint in colorectal cancer (CRC), as a potential target for RNA editing. We performed transcriptome sequencing analysis and experimental validation in two Chinese CRC cohorts. PVR and ADAR expressions significantly increased in CRC tumors and showed positive correlations in both cohorts, coupled with upregulated PVR RNA editing in CRC tumors. Manipulation of ADAR expression by over-expression or knockdown substantially changed PVR expression and RNA editing in HTC116 CRC cells. Luciferase reporter and actinomycin D assays further revealed that RNA editing in PVR 3'-UTR could upregulate PVR RNA expression, probably by increasing the RNA stability. By increasing PVR expression, ADAR-mediate RNA editing might contribute to tumor- and immune-related gene functions and pathways in CRC. Moreover, a signature combining PVR RNA editing and expression showed promising predictive performance in CRC diagnosis in both Chinese CRC cohorts. Our findings thus highlight the importance of ADAR-mediated RNA editing in PVR up-regulation in CRC tumors and provide new insight into the application of PVR RNA editing as a novel diagnostic biomarker for CRC.
最近的研究表明,肿瘤免疫治疗耐药性受到 ADAR 介导的 RNA 编辑的影响,但其靶标仍不清楚。我们目前的研究确定了脊髓灰质炎病毒受体(PVR)癌基因,它编码结直肠癌(CRC)中的免疫检查点,是 RNA 编辑的潜在靶标。我们在两个中国 CRC 队列中进行了转录组测序分析和实验验证。PVR 和 ADAR 的表达在 CRC 肿瘤中显著增加,并且在两个队列中均呈正相关,同时 CRC 肿瘤中 PVR RNA 编辑也上调。通过过表达或敲低 ADAR 表达对 HTC116 CRC 细胞中的 PVR 表达和 RNA 编辑进行了操纵。荧光素酶报告基因和放线菌素 D 测定进一步表明,PVR 3'-UTR 中的 RNA 编辑可以上调 PVR RNA 表达,可能是通过增加 RNA 稳定性实现的。通过增加 PVR 表达,ADAR 介导的 RNA 编辑可能有助于 CRC 中肿瘤和免疫相关基因功能和途径。此外,结合 PVR RNA 编辑和表达的特征在两个中国 CRC 队列的 CRC 诊断中均显示出有前途的预测性能。因此,我们的研究结果强调了 ADAR 介导的 RNA 编辑在 CRC 肿瘤中 PVR 上调中的重要性,并为 PVR RNA 编辑作为 CRC 新型诊断生物标志物的应用提供了新的见解。